Schedule 13G ownership disclosure

EVOKE PHARMA INC

Common Stock, par value $0.0001 · CUSIP: 30049G302

Event date: 2025-03-31

Filing-level shares
61,274.00
Percent of class
3.9%
  • Lytton, Laurence W.

    Shares: 61,274.00 · Class: 3.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000935836-25-000375
Form type
SCHEDULE 13G/A
Filer
Evoke Pharma Inc
CIK
CIK 1403708
Filed
May 15, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub